A Phase 2 interventional study of Fuling Yunhua Granules and Dihuang Baoyuan Granules in Diabetes Mellitus, Type 2, Diabetes and Type2diabetes, sponsored by Beijing Supreme Life Pharmaceutical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Beijing Supreme Life Pharmaceutical Technology Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 909 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 228 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.
Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 509th largest by enrollment of the 767 interventional ones that give a count, is one of 83 that started in 2024, is one of 61 in phase 2, and was the 690th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →205 of the 909 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in China, United States, Brazil and 7 more countries
Ages 18+
BrightGene Bio-Medical Technology Co., Ltd. · Sites in China
Ages 18–75
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–75
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
909 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 142 · Phase 2 90 · Phase 3 216 · Phase 4 155
First in 1998; this study’s year is marked. 83 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 95 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 199 across the 767 interventional studies, 593 across the 141 observational. Of the 518 that completed or were terminated, 123 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
448 of 909 have an industry lead sponsor. The 10 most frequent:
Beijing Supreme Life Pharmaceutical Technology Co., Ltd. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Beijing Supreme Life Pharmaceutical Technology Co., Ltd. has 3 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
54 of the studies in Diabetes Mellitus, Type 2 with a site in China that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07060456Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin | 2027-02 |
| NCT07082114Phase 3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus | 2027-02-16 |
| NCT07156500Phase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone | 2027-03-30 |
| NCT07156539Phase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.A Phase 3 Study of HS-20094 in Patients With T2DM | 2027-03-30 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 54 to your calendar (.ics) → With an account.
Among the 909 studies in Diabetes Mellitus, Type 2 with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this investigator-initiated clinical trial is to investigate the efficacy and safety of sequential therapy of Fuling Yunhua Granules (prescription A) and Dihuang Baoyuan Granule (prescription B) in the treatment of type 2 diabetes patients with poor glycemic control after diet and exercise intervention.
This is a multicenter, randomized, double-blind, placebo-controlled study, including a up to 2-week screening period, a 1-week baseline period, a 12-week treatment period and a 1-week follow-up period.
72 participants who meet the enrollment requirements will enter the baseline period, during which 7 days of CGM data will be collected. After entering the treatment period, participants will be randomly assigned to prescription ABA group, prescription ABA-matched placebo group, prescription BAB group and prescription BAB-matched placebo group in a ratio of 2:1:2:1 and receive corresponding treatment.
It is expected that an interim analysis will be conducted after 30 participants have completed 4 weeks of treatment and 4 weeks of their data is obtained. Based on the CGM data of the participants in the 4th week of treatment, the change of TIR in the 4th week compared with the baseline will be analyzed, and the IDMC will make a decision based on the results of this analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any laboratory test meets any of the following criteria during screening:
(ALT) or aspartate aminotransferase (AST) > (ULN) × 2.5 times (eGFR) calculated using the CKD-EPI formula \< 60 mL/min /1.73m2 Total (TBIL)>ULN×1.5 times Fasting triglyceride (TG)>5.7 mmol/L Fasting C-peptide \<0.8 ng/ml (or 0.26 nmol/L)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fuling Yunhua Granules and Dihuang Baoyuan Granules
Drug: Fuling Yunhua Granules
Fuling Yunhua Granules and Dihuang Baoyuan Granules
Drug: Dihuang Baoyuan Granules
Fuling Yunhua Granules placebo and Dihuang Baoyuan Granules placebo
Drug: Fuling Yunhua Granules matched placebo/Dihuang Baoyuan Granules matched placebo
Fuling Yunhua Granules
Also known as: prescription A
Dihuang Baoyuan Granules
Also known as: prescription B
Fuling Yunhua Granules placebo/Dihuang Baoyuan Granules placebo
Also known as: prescription A matched placebo/B matched placebo
Change in HbA1c Concentrations (%) From Baseline
Change in HbA1c concentrations (%) from baseline is the numerical difference between a participant's hemoglobin A1c (HbA1c) level at a specified follow-up time point(s) and their baseline level (initial assessment before intervention). HbA1c, a glycated hemoglobin biomarker, reflects average blood glucose over 8-12 weeks. Venous blood is collected via standard phlebotomy, and HbA1c is quantified using a laboratory-certified method (e.g., high-performance liquid chromatography \[HPLC\] or immunoassay) for accuracy. Calculated as: Follow-up HbA1c (%) - Baseline HbA1c (%), positive values mean increased average blood glucose, negative values mean decreased. This metric evaluates intervention efficacy (e.g., medications, lifestyle modifications) for glycemic control in diabetes or prediabetes populations.
Time frame: 12 weeks
Change in FPG (mmol/L) From Baseline
Change in Fasting Plasma Glucose (FPG) (mmol/L) from baseline is the numerical difference between a participant's FPG level at follow-up and their baseline FPG. FPG measures plasma glucose concentration after an 8-12 hour fast, reflecting overnight glycemic control. Venous blood samples are collected via standard phlebotomy, with glucose quantified using laboratory methods (e.g., hexokinase assay). Calculated as: Follow-up FPG (mmol/L) - Baseline FPG (mmol/L), positive values indicate increased fasting glucose, negative values a decrease. This metric assesses intervention efficacy in regulating fasting glycemia, critical for diabetes management.
Time frame: 12 weeks
The Proportion of Participants Who Achieved HbA1c Target
The proportion of participants who achieved HbA1c target (HbA1c\<7.0% and \<6.5% Patient percentage)
Time frame: 12 weeks
Changes in TIR From Baseline
Changes in Time in Range (TIR) from baseline refers to the difference between a participant's TIR at follow-up and their baseline TIR. TIR is the percentage of time blood glucose levels stay within a target range (typically 3.9-10.0 mmol/L \[70-180 mg/dL\] for most people with diabetes) over a specified period, measured via continuous glucose monitoring (CGM) devices. Calculated as: Follow-up TIR (%) - Baseline TIR (%), positive values indicate increased time in target range, negative values a decrease. This metric assesses glycemic stability and intervention effectiveness (e.g., medication adjustments, lifestyle changes) in managing blood glucose control.
Time frame: 12 weeks
Changes in TBR From Baseline
Changes in Time Below Range (TBR) from baseline is the difference between a participant's TBR at follow-up and their baseline TBR. TBR is the percentage of time blood glucose levels fall below a target range (e.g., \<3.9 mmol/L \[70 mg/dL\] for adults) over a specified period, measured via continuous glucose monitoring (CGM). Calculated as: Follow-up TBR (%) - Baseline TBR (%), positive values indicate increased time below range, negative values a decrease. This metric evaluates risks of hypoglycemia and intervention impact on maintaining glucose above target levels.
Time frame: 12 weeks
Changes in TAR From Baseline
Changes in Time Above Range (TAR) from baseline refers to the difference between a participant's TAR at follow-up and their baseline TAR. TAR is the percentage of time blood glucose levels exceed a target range (e.g., \>10.0 mmol/L \[180 mg/dL\] for most adults with diabetes) over a specified period, measured via continuous glucose monitoring (CGM). Calculated as: Follow-up TAR (%) - Baseline TAR (%), positive values indicate increased time above range, negative values a decrease. This metric assesses risks of hyperglycemia and intervention effectiveness in keeping glucose within target levels.
Time frame: 12 weeks
Changes in MAGE From Baseline
Changes in Mean Amplitude of Glycemic Excursions (MAGE) from baseline is the difference between a participant's MAGE at follow-up and their baseline MAGE. MAGE quantifies the average magnitude of significant blood glucose fluctuations (exceeding a threshold, typically 1.4 mmol/L \[25 mg/dL\]) over a specified period, derived from continuous glucose monitoring (CGM) data. Calculated as: Follow-up MAGE - Baseline MAGE, higher values indicate greater glycemic variability, lower values more stable glucose. This metric evaluates intervention impact on reducing glucose swings, relevant for assessing glycemic stability in diabetes management.
Time frame: 12 weeks
Change From Baseline in Total Cholesterol (TC) at Week 12
TTotal cholesterol (TC) was measured in venous blood samples and reported in mmol/L. Change from baseline was calculated as the TC value at Week 12 minus the baseline TC value. Negative values indicate a reduction in total cholesterol.
Time frame: 12 weeks
Change From Baseline in Body Weight at Week 12
Body weight was measured in kilograms. Change from baseline was calculated as body weight at Week 12 minus baseline body weight. Negative values indicate weight loss, and positive values indicate weight gain.
Time frame: 12 weeks
| Milestone | Prescription ABA | Prescription BAB | Prescription Fuling Yunhua Granules Placebo/BAB-matched Placebo |
|---|---|---|---|
| Started | 32 | 32 | 31 |
| Completed | 26 | 32 | 30 |
| Not completed | 6 | 0 | 1 |
Change in HbA1c concentrations (%) from baseline is the numerical difference between a participant's hemoglobin A1c (HbA1c) level at a specified follow-up time point(s) and their baseline level (initial assessment before intervention). HbA1c, a glycated hemoglobin biomarker, reflects average blood glucose over 8-12 weeks. Venous blood is collected via standard phlebotomy, and HbA1c is quantified using a laboratory-certified method (e.g., high-performance liquid chromatography \[HPLC\] or immunoassay) for accuracy. Calculated as: Follow-up HbA1c (%) - Baseline HbA1c (%), positive values mean increased average blood glucose, negative values mean decreased. This metric evaluates intervention efficacy (e.g., medications, lifestyle modifications) for glycemic control in diabetes or prediabetes populations.
| percentage of HbA1c | Prescription ABA | Prescription BAB | Prescription ABA/BAB-matched Placebo |
|---|---|---|---|
| Baseline HbA1c | 8.17 ± 0.767 | 8.31 ± 1.031 | 8.25 ± 0.819 |
| HbA1c at Week 12 | 7.20 ± 0.971 | 7.27 ± 0.963 | 7.93 ± 1.004 |
Change in Fasting Plasma Glucose (FPG) (mmol/L) from baseline is the numerical difference between a participant's FPG level at follow-up and their baseline FPG. FPG measures plasma glucose concentration after an 8-12 hour fast, reflecting overnight glycemic control. Venous blood samples are collected via standard phlebotomy, with glucose quantified using laboratory methods (e.g., hexokinase assay). Calculated as: Follow-up FPG (mmol/L) - Baseline FPG (mmol/L), positive values indicate increased fasting glucose, negative values a decrease. This metric assesses intervention efficacy in regulating fasting glycemia, critical for diabetes management.
| mmol/L | Prescription ABA | Prescription BAB | Prescription ABA/BAB-matched Placebo |
|---|---|---|---|
| Baseline FPG | 9.048 ± 1.628 | 9.583 ± 1.5431 | 9.149 ± 1.8092 |
| FPG (mmol/L) after 12 weeks of treatment | 7.672 ± 1.3091 | 7.993 ± 1.6283 | 9.170 ± 2.0752 |
| Relative change in FPG from baseline after 12 weeks of treatment (mmol/L) | -1.463 ± 1.2551 | -1.590 ± 1.6809 | 0.027 ± 2.1562 |
The proportion of participants who achieved HbA1c target (HbA1c\<7.0% and \<6.5% Patient percentage)
| Participants | Prescription ABA | Prescription BAB | Prescription ABA-matched Placebo/ BAB-matched Placebo |
|---|---|---|---|
| HbA1c<7%at Week 12 | 14 | 13 | 3 |
| HbA1c<6.5%at Week 12 | 8 | 7 | 1 |
Changes in Time in Range (TIR) from baseline refers to the difference between a participant's TIR at follow-up and their baseline TIR. TIR is the percentage of time blood glucose levels stay within a target range (typically 3.9-10.0 mmol/L \[70-180 mg/dL\] for most people with diabetes) over a specified period, measured via continuous glucose monitoring (CGM) devices. Calculated as: Follow-up TIR (%) - Baseline TIR (%), positive values indicate increased time in target range, negative values a decrease. This metric assesses glycemic stability and intervention effectiveness (e.g., medication adjustments, lifestyle changes) in managing blood glucose control.
| percentage of TIR | Prescription ABA | Prescription BAB | Prescription Fuling Yunhua Granules Placebo/BAB-matched Placebo |
|---|---|---|---|
| Time in Range (TIR) Baseline | 52.59 ± 25.287 | 46.26 ± 23.821 | 56.13 ± 21.859 |
| Time in Range (TIR)After 12 Weeks | 74.55 ± 23.379 | 77.25 ± 25.24 | 57.11 ± 63.99 |
| Changes in TIR from baseline | 20.29 ± 29.827 | 30.81 ± 26.159 | -0.42 ± 19.604 |
Changes in Time Below Range (TBR) from baseline is the difference between a participant's TBR at follow-up and their baseline TBR. TBR is the percentage of time blood glucose levels fall below a target range (e.g., \<3.9 mmol/L \[70 mg/dL\] for adults) over a specified period, measured via continuous glucose monitoring (CGM). Calculated as: Follow-up TBR (%) - Baseline TBR (%), positive values indicate increased time below range, negative values a decrease. This metric evaluates risks of hypoglycemia and intervention impact on maintaining glucose above target levels.
| percentage of TBR | Prescription ABA | Prescription BAB | Prescription ABA/BAB-matched Placebo |
|---|---|---|---|
| Time Below Range (TBR) Baseline | 0.37 ± 1.145 | 0.13 ± 0.479 | 0.13 ± 0.624 |
| Time Below Range After 12 Weeks(TBR) | 0.35 ± 1.221 | 0.46 ± 1.261 | 0.38 ± 1.372 |
| Changes in TBR from baseline | 0.08 ± 1.569 | 0.32 ± 1.402 | 0.36 ± 1.342 |
Changes in Time Above Range (TAR) from baseline refers to the difference between a participant's TAR at follow-up and their baseline TAR. TAR is the percentage of time blood glucose levels exceed a target range (e.g., \>10.0 mmol/L \[180 mg/dL\] for most adults with diabetes) over a specified period, measured via continuous glucose monitoring (CGM). Calculated as: Follow-up TAR (%) - Baseline TAR (%), positive values indicate increased time above range, negative values a decrease. This metric assesses risks of hyperglycemia and intervention effectiveness in keeping glucose within target levels.
| percentage of TAR | Prescription ABA | Prescription BAB | Prescription ABA/BAB-matched Placebo |
|---|---|---|---|
| TAR Baseline | 47.04 ± 25.460 | 53.61 ± 24.073 | 43.74 ± 21.880 |
| TAR After 12 Weeks | 25.09 ± 23.695 | 22.29 ± 25.427 | 42.51 ± 29.108 |
| Changes in TAR from baseline | -20.37 ± 30.113 | -31.12 ± 26.531 | 0.05 ± 19.846 |
Changes in Mean Amplitude of Glycemic Excursions (MAGE) from baseline is the difference between a participant's MAGE at follow-up and their baseline MAGE. MAGE quantifies the average magnitude of significant blood glucose fluctuations (exceeding a threshold, typically 1.4 mmol/L \[25 mg/dL\]) over a specified period, derived from continuous glucose monitoring (CGM) data. Calculated as: Follow-up MAGE - Baseline MAGE, higher values indicate greater glycemic variability, lower values more stable glucose. This metric evaluates intervention impact on reducing glucose swings, relevant for assessing glycemic stability in diabetes management.
| mmol/l | Prescription ABA | Prescription BAB | Prescription ABA/BAB-matched Placebo |
|---|---|---|---|
| Baseline | 6.80 ± 2.141 | 7 ± 1.646 | 6.95 ± 1.816 |
| After 12 Weeks | 5.3 ± 2.016 | 4.95 ± 1.78 | 6.35 ± 1.414 |
| Changes in MAGE from baseline | -1.27 ± 1.896 | -2.01 ± 1.766 | -0.54 ± 1.645 |
TTotal cholesterol (TC) was measured in venous blood samples and reported in mmol/L. Change from baseline was calculated as the TC value at Week 12 minus the baseline TC value. Negative values indicate a reduction in total cholesterol.
| mmol/L | Prescription ABA | Prescription BAB | Prescription ABA/BAB-matched Placebo |
|---|---|---|---|
| Total Cholesterol at Baseline | 5.253 ± 1.0526 | 4.978 ± 0.9903 | 5.171 ± 0.9263 |
| Total Cholesterol at Week 12 | 4.854 ± 1.0387 | 4.793 ± 0.8504 | 5.101 ± 1.1281 |
| Change From Baseline at Week 12 from baseline | -0.468 ± 0.6479 | -0.186 ± 0.7691 | -0.033 ± 0.8066 |
Body weight was measured in kilograms. Change from baseline was calculated as body weight at Week 12 minus baseline body weight. Negative values indicate weight loss, and positive values indicate weight gain.
| kg | Prescription ABA | Prescription BAB | Prescription ABA-matched Placebo/ BAB-matched Placebo |
|---|---|---|---|
| Body Weight at Baseline | 69.20 ± 9.347 | 73.53 ± 13.634 | 69.39 ± 13.921 |
| Body Weight at Week 12 | 68.71 ± 9.676 | 73.66 ± 13.927 | 68.78 ± 13.858 |
| Change From Baseline in Body Weight at Week 12 | -0.41 ± 2.070 | 0.13 ± 1.678 | -0.54 ± 1.768 |
Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prescription ABA | 0/32 (0%) | 1/32 (3.1%) | 24/32 (75%) |
| Prescription BAB | 0/32 (0%) | 0/32 (0%) | 19/32 (59.4%) |
| Prescription ABA-matched Placebo/ BAB-matched Placebo | 0/31 (0%) | 0/31 (0%) | 12/31 (38.7%) |
| Event | Prescription ABA | Prescription BAB | Prescription ABA-matched Placebo/ BAB-matched Placebo |
|---|---|---|---|
| Microvascular Coronary Artery DiseaseCardiac disorders | 1/32 | 0/32 | 0/31 |
| Event | Prescription ABA | Prescription BAB | Prescription ABA-matched Placebo/ BAB-matched Placebo |
|---|---|---|---|
| diarrheaGastrointestinal disorders | 11/32 | 9/32 | 3/31 |
| Abnormal liver functionHepatobiliary disorders | 6/32 | 2/32 | 1/31 |
| Gastrointestinal distensionGastrointestinal disorders | 2/32 | 4/32 | 4/31 |
| Urinary tract infectionsInfections and infestations | 4/32 | 0/32 | 3/31 |
| NauseaGastrointestinal disorders | 3/32 | 3/32 | 0/31 |
| Upper respiratory tract infectionsInfections and infestations | 3/32 | 1/32 | 1/31 |
95 participants were randomly assigned to the 12-week treatment period (BAB regimen group, n=32; ABA regimen group, n=32; Placebo group, n=31)
| Age, Continuous(years) | Prescription ABA | Prescription BAB | Prescription ABA/BAB-matched Placebo | Total |
|---|---|---|---|---|
| Mean | 56.7 ± 11.51 | 52.8 ± 9.62 | 57.2 ± 8.79 | 55.5 ± 10.14 |
| Sex: Female, Male(Participants) | Prescription ABA | Prescription BAB | Prescription ABA/BAB-matched Placebo | Total |
|---|---|---|---|---|
| Female | 17 | 15 | 14 | 46 |
| Male | 15 | 17 | 17 | 49 |
| Race/Ethnicity, Customized(participants) | Prescription ABA | Prescription BAB | Prescription ABA/BAB-matched Placebo | Total |
|---|---|---|---|---|
| Asian | 32 | 32 | 31 | 95 |
| Body Mass Index (BMI)(kg/m^2) | Prescription ABA | Prescription BAB | Prescription ABA/BAB-matched Placebo | Total |
|---|---|---|---|---|
| Mean | 25.03 ± 2.459 | 26.58 ± 3.911 | 25.20 ± 3.202 | 25.61 ± 3.286 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — There is no plan to make individual participant data (IPD) available to other researchers.
Ran from Jul 2024 to primary completion in Jan 2025, 5 months.
Results were first posted in Oct 2026, 1 year 8 months after primary completion.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 5 months is below that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Supreme Life Pharmaceutical Technology Co., Ltd.